Pharmaceutical Executive Daily: FDA Approves Onswik

Sep 24, 05:44 PM
Headliner
Share
Subscribe

InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.

Share
Subscribe
Next
Pharmaceutical Executive Daily: Mike Doustdar Open to Direct Listing for Novo Shares
Top episodes
Healthcare Marketing Strategies for Reaching Diverse Audiences
by Pharmaceutical Executive
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
by Pharmaceutical Executive
Key Findings of the NIAGARA and HIMALAYA Trials
by Pharmaceutical Executive